MIRCERA 200mcg/0.3ml Price

Overview

Welcome to Dwaey, specifically on MIRCERA 200mcg/0.3ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Methoxy polyethylene glycol-epoetin beta (Pegzerepoitin alfa).
MIRCERA 200mcg/0.3ml is available in the market in concentration 200mcg/0.3ml and in the form of Injection/Solution for.

F. HOFFMANN-LA ROCHE LTD. is the producer of MIRCERA 200mcg/0.3ml and it is imported from SWITZERLAND, The most popular alternatives of MIRCERA 200mcg/0.3ml are listed downward .

Mode Of Action

Methoxy Polyethyelene Glycol-Epoetin Beta is an erythropoietin receptor activator w/ greater activity as well as increased half-life, in contrast to erythropoietin.

Indication

• Anaemia associated with chronic kidney disease

Precaution

Discontinue if pure red cell aplasia. Adequate control of BP. Hemoglobinopathies, seizures, platelet level >500 x 109/L. Patients <18 yr. Lactation: not known if excreted in breast milk, use caution

Side Effects

• >10% Hypertension (13%)
• Diarrhea (11%)
• Nasopharyngitis (11%) 1-10% Headache (9%)
• Upper respiratory tract infection (9%)
• Cough (6%)
• Hypotension (5%)
• Urinary tract infection (5%)
• Procedural arteriovenous fistula thrombosis (5%) Frequency Not Defined Coronary artery disease
• Anemia
• Septic shock
• Serious cardiovascular and thromboembolic events
• Seizures
• Immunogenicity related PRCA
• Increased mortality and/or tumor progression in cancer patients
• Increased mortality
• Concomitant termination of other CRF therapy
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis

Contra indication

Hypersensitivity. Uncontrolled HTN.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks